In addition to the sale, Dickinson exercised several stock options, acquiring a total of 248,645 shares at prices between $57.92 and $73.77. This transaction was made under the previously established trading system of Rule 10b5-1, which was adopted on August 29, 2024. After this transaction, Dickinson retains direct ownership of 138,919 shares in Gilead Sciences (NASDAQ: ). InvestingPro data shows that the stock is currently well-known, with 11 additional exclusive details available to subscribers, including a detailed analysis of the company’s earnings history and growth potential. InvestingPro data shows that the stock is currently well-known, with 11 additional exclusive details available to subscribers, including a detailed analysis of the company’s earnings history and growth potential.
In addition to the sale, Dickinson exercised several stock options, acquiring a total of 248,645 shares at prices between $57.92 and $73.77. These transactions are conducted under the pre-established trading plan of Rule 10b5-1, which was adopted on August 29, 2024.
Following this transaction, Dickinson retains direct ownership of 138,919 shares in Gilead Sciences.
In other recent news, Gilead Sciences has been making significant progress in its ongoing projects. The company announced an agreement with Tubulis to develop an antibody-drug conjugate for the treatment of solid tumors. This partnership could reach $415 million in payments. Gilead also demonstrated high efficacy in a Phase 3 trial of its investigational HIV prevention drug, lenacapavir, which showed a 96% reduction in HIV infection.
In addition, Gilead issued $3.5 billion in senior notes for general corporate purposes, including repaying existing debt. Analysts at RBC Capital Markets and Citi have expressed confidence in Gilead, maintaining a Sector Perform rating and giving a Buy rating respectively.
In other cases, Gilead reported encouraging interim results from its Phase 3 ASSURE study with Livdelzi, a treatment for primary biliary cholangitis. The study revealed that 81% of patients achieved a composite biochemical response, and 41% achieved normal levels of alkaline phosphatase. These recent developments highlight Gilead’s continued commitment to the treatment and prevention of disease, as well as its potential for growth and profitability.
This article was created with the support of AI and reviewed by an editor. For more information see our T&C.
